Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.…
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Revelation Biosciences (NASDAQ: REVB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 3.500 USD on 20 November 2026, down 87.6% over 52 weeks. Its 52-week range is 3.080 USD to 40.60 USD: the price is 91.4% below the high and 13.6% above the low.
Its market capitalisation is 1.99M USD.
Revelation Biosciences reports return on equity of -100.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.32M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.